Ocrelizumab
From MEpedia, a crowd-sourced encyclopedia of ME and CFS science and history
Ocrelizumab is a pharmaceutical treatment developed for people with primary-progressive Multiple sclerosis (MS). It is an immunosuppressive drug that targets mature B cell lymphocytes which have the CD20 antibody on their surface. The therapy is similar to rituximab.[1] Ocrelizumab is registered under the brand name Ocrevus, and on May 28, 2017, received approval by the U.S. Food and Drug Administration for treating MS.[2][3]
Learn more[edit | edit source]
- 2017, After 40-year odyssey, first drug for aggressive MS wins FDA approval
- 2016, Wrapping Up Multiple Sclerosis
- 2016, New MS Drug Shows 'Breakthrough' Promise for Advanced Disease
See also[edit | edit source]
References[edit | edit source]
- ↑ http://www.nationalmssociety.org/About-the-Society/News/Ocrelizumab-Granted-Breakthrough-Therapy-Designat
- ↑ FDA Approves Genentech’s OCREVUS™ (Ocrelizumab) For Relapsing and Primary Progressive Forms of Multiple Sclerosis
- ↑ http://www.msn.com/en-us/health/medical/new-ms-drug-shows-breakthrough-promise-for-advanced-disease/ar-BBxsxoC?li=BBnbfcL
 | This article is a stub. |
